GLP-1 Medications Might Enhance Male Fertility
Experts suggest that using GLP-1 medications for weight loss could positively affect male fertility.
At the recent ENDO 2026 conference in Chicago, research highlighted the strong correlation between obesity and fertility issues in men.
Excess weight may disrupt the hypothalamic-pituitary-gonadal (HPG) axis, which plays a crucial role in testosterone production. This disruption can lead to low testosterone levels, a condition known as functional hypogonadism, and can also affect semen quality.
The researchers looked into how GLP-1 weight-loss drugs influence reproductive hormones and metabolic functions by analyzing data from men aged 18 to 65 who were using these medications.
A systematic review of five randomized controlled trials examined testosterone levels, hormones related to sperm production, and the transportation of sex hormones in the bloodstream. The analysis included factors like semen quality, weight, BMI, cholesterol, and blood sugar levels.
The findings indicated that GLP-1 medications might not hinder male hormone levels. Men with obesity linked to low testosterone may see improvements in testosterone levels, sperm quality, and overall metabolic health during weight loss.
In one particular study spanning four weeks, the GLP-1 drug dulaglutide showed no major alterations in reproductive hormones or sexual function.
Conversely, a separate trial lasting 16 weeks with liraglutide demonstrated positive effects on hormones for obese men experiencing low testosterone likely due to their weight. Interestingly, liraglutide was found to be more beneficial for health than hormone replacement therapy.
Another study involving liraglutide reported enhancements in sperm concentration and count.
A 24-week trial utilizing semaglutide, branded as Ozempic and Wegovy, revealed improvements in sperm shape and bad cholesterol levels, while maintaining overall testosterone.
Since only five trials were considered, the current evidence is somewhat limited, prompting the need for further investigations to establish a more definite connection.
In summarizing their findings, the study authors noted that GLP-1s do not appear to severely suppress the male HPG axis and may facilitate improvements in reproductive hormones and semen metrics in obese men facing low testosterone, predominantly in the context of weight loss.
However, they emphasized the necessity for larger, targeted studies to effectively assess male reproductive outcomes.
Dr. Anthony Puopolo, a men’s health expert, expressed his thoughts on these results, noting that this research provides promising initial evidence that GLP-1 medications could help enhance testosterone levels in obese men with low testosterone.
While he mentioned further studies are crucial, he remained hopeful about the potential role of GLP-1s in boosting male fertility, suggesting they might serve as a more suitable option than testosterone replacement therapy, which can negatively affect reproductive functions.
